At a glance
- Originator Otsuka Pharmaceutical
- Class Antigouts
- Mechanism of Action Xanthine oxidase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Gout
Most Recent Events
- 07 Aug 1995 Discontinued-II for Gout in Japan (PO)
- 02 Jun 1995 Investigation in Gout in Japan (PO)